Replies to post #32561 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Q1 reported: $600K
Q2 reported: $2M
Q3 reported: $1.2M
Q4 guesstimate: $1.2M($1M from FocalinXR and $200K from SeroquelXR)

For a total of $5M which will represent a YOY revenue increase of 1.5X their reported $2M in 2016.

And with PAR finally launching the final 2 strengths of FocalinXR on day 1 of IPCI's 2018 fiscal calendar year(which started on Dec 1st, 2017)...that puts IPCI already on track to match the expected 2017 revs of $5M in revenue from FocalinXR alone in 2018(assuming $1.25M per Q from the PAR/FocalinXR deal).

So further to the above points, any revenue realized from Mallinkrodt's ongoing SeroquelXR commercialization endeavors throughout 2018 already puts IPCI on track to another expected increase in their YOY revenue growth...we just don't know if Mallinkrodt's going to improve SeroquelXR sales...nor do we know if Mallinkrodt's gonna be doing much if/when the FDA grants ANDA approvals on Pristiq or Lamictal.

So bare minimum, IPCI's already on track to exceed $5M in revenue in fiscal year 2018...but there's just no way of determining how much because so far anyways Mallinkrodt hasn't been driving much SeroquelXR sales growth. And even if the FDA approves the other 2 already partnered with MNK ANDA's if they commercialize both Pristiq and Lamictal like they're commercializing SeroquelXR so far...we can't expect much revenue from all 3 ANDA's already partnered with MNK which in and of itself takes potential positives and instead creates negativity and uncertainty lol.

The only real progress that may get IPCI uptrending again imo is launching human trials on PODRAS and launching the oral and nasal studies on OxyContin.

If those 2 material developments initiate soon then we should finally be on track to putting the extended market apathy phase this stocks been suffering through behind us.

I'm not holding my breath for anything positive anymore though...just gonna ride IPCI through this summer and hope that some of the positive material developments they've at least telegraphed and given timelines on begin to occur glta

[tilator]

Revenue much lower then expected, expenses .... Are you sure about that? What about their paychecks???

Well - I just count. Paychecks are less than paychecks + HAP test costs. If there were these costs. Now there can't be because FDA didn't yet allow these tests.

If you know better, just let us know.